Leading neurologists and cardiologists came together to present the latest research in the field at the American Heart Association/American Stroke Association’s International Stroke Conference for 2024, held in Arizona between February 7-9.
Here is the limbic‘s pick of research results and findings at ISC 2024.
Earlier anticoagulation reversal associated with improved survival for ICH
Earlier administration of anticoagulation reversal in patients with intracerebral haemorrhage is associated with reduced in-hospital mortality or discharge to hospice and increased likelihood of discharge home, a US study suggests.
The findings, which were published in JAMA Neurology [link here] and presented at ISC 2024, should encourage intensive efforts to accelerate the evaluation and treatment of such patients in emergency settings, said the researchers.
They analysed data from 9492 patients (median age 77, 45% female) in the American Heart Association’s Get With The Guidelines Stroke registry.
From 2015 to 2021, patients in 465 hospitals presented with anticoagulation-associated intracerebral haemorrhage (ICH) within 24 hours of symptom onset.
Some 7469 (78.7%) patients received reversal therapy, including patients on warfarin (85%) and those on a non–vitamin K antagonist oral anticoagulant (70%).
For those with documented workflow times, findings showed the median onset-to-treatment time was 232 minutes and the median door-to-treatment time was 82 minutes, with a door-to-treatment time of 60 minutes or less in 1449 (27.7%).
A door-to-treatment time of 60 minutes or less was associated with decreased mortality and discharge to hospice (adjusted odds ratio, 0.82), but there were no differences in functional outcome between the groups, said the authors led by Yale Centre for Brain and Mind Health, Yale University School of Medicine.
Factors associated with faster administration of reversal interventions included white race, higher systolic blood pressure, and lower stroke severity.
Tenecteplase for stroke – a benefit beyond 4.5 hours?
Tenecteplase therapy initiated 4.5 to 24 hours after stroke onset is unlikely to improve outcomes for patients with occlusions of the middle cerebral artery or internal carotid artery, a US study suggests.
The TIMELESS (Thrombolysis in Imaging Eligible, Late Window Patients to Assess the Efficacy and Safety of Tenecteplase) trial compared tenecteplase or placebo administered to 458 patients with ischemic stroke 4.5 to 24 hours after they were last known to be well.
Patients were only included if they had evidence of occlusion of the middle cerebral artery or internal carotid artery and salvageable tissue as determined on perfusion imaging.
Findings published in the New England Journal of Medicine [link here] and presented at ISC 2024 showed no significant between-group differences, with the median score on the modified Rankin scale at 90 days 3 in each group. The adjusted common odds ratio for the distribution of scores for tenecteplase as compared with placebo was 1.13.